CA2876359C - Phosphoramidic acid prodrugs of 5-[5-phenyl-4-(pyridin-2-ylmethylamino) quinazolin-2-yl] pyridine-3-sulfonamide - Google Patents
Phosphoramidic acid prodrugs of 5-[5-phenyl-4-(pyridin-2-ylmethylamino) quinazolin-2-yl] pyridine-3-sulfonamide Download PDFInfo
- Publication number
- CA2876359C CA2876359C CA2876359A CA2876359A CA2876359C CA 2876359 C CA2876359 C CA 2876359C CA 2876359 A CA2876359 A CA 2876359A CA 2876359 A CA2876359 A CA 2876359A CA 2876359 C CA2876359 C CA 2876359C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pyridin
- compounds
- quinazolin
- acetonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657913P | 2012-06-11 | 2012-06-11 | |
| US61/657,913 | 2012-06-11 | ||
| PCT/US2013/044882 WO2013188254A1 (en) | 2012-06-11 | 2013-06-10 | Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2876359A1 CA2876359A1 (en) | 2013-12-19 |
| CA2876359C true CA2876359C (en) | 2020-01-21 |
Family
ID=48670111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2876359A Active CA2876359C (en) | 2012-06-11 | 2013-06-10 | Phosphoramidic acid prodrugs of 5-[5-phenyl-4-(pyridin-2-ylmethylamino) quinazolin-2-yl] pyridine-3-sulfonamide |
Country Status (34)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9050345B2 (en) * | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| US9403834B2 (en) * | 2013-03-11 | 2016-08-02 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| CN105008366B (zh) * | 2013-03-11 | 2017-11-14 | 百时美施贵宝公司 | 作为钾离子通道抑制剂的吡咯并哒嗪类化合物 |
| KR20180084049A (ko) * | 2015-11-19 | 2018-07-24 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | 제약 화합물의 아민 전구약물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| GB9514380D0 (en) * | 1995-07-13 | 1995-09-13 | Knoll Ag | Therapeutic agents |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| ID26984A (id) | 1998-07-06 | 2001-02-22 | Bristol Myers Squibb Co | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda |
| ES2215474B1 (es) | 2002-12-24 | 2005-12-16 | J. URIACH & CIA S.A. | Nuevos derivados de fosforamida. |
| AR049847A1 (es) | 2004-07-29 | 2006-09-06 | Merck & Co Inc | Inhibidores de los canales de potasio |
| EP1838690A2 (en) * | 2004-12-21 | 2007-10-03 | Devgen N.V. | Compounds with kv4 ion channel activity |
| EP2473487B1 (en) | 2009-09-03 | 2016-10-26 | Bristol-Myers Squibb Company | Quinazolines as potassium ion channel inhibitors |
| AU2010289321A1 (en) | 2009-09-04 | 2012-04-05 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| NZ604423A (en) * | 2010-06-24 | 2015-01-30 | Alkermes Pharma Ireland Ltd | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| US9050345B2 (en) * | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| JP2016516691A (ja) * | 2013-03-11 | 2016-06-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | カリウムイオンチャネル阻害剤としてのイソキノリン |
| US9242966B2 (en) * | 2013-03-11 | 2016-01-26 | Bristol-Myers Squibb Company | Phthalazines as potassium ion channel inhibitors |
-
2013
- 2013-06-10 PT PT137304440T patent/PT2858987T/pt unknown
- 2013-06-10 SM SM20180369T patent/SMT201800369T1/it unknown
- 2013-06-10 AR ARP130102043 patent/AR091402A1/es not_active Application Discontinuation
- 2013-06-10 JP JP2015517321A patent/JP6234450B2/ja not_active Expired - Fee Related
- 2013-06-10 SG SG11201408076WA patent/SG11201408076WA/en unknown
- 2013-06-10 US US14/406,543 patent/US9238666B2/en active Active
- 2013-06-10 BR BR112014030629-0A patent/BR112014030629B1/pt active IP Right Grant
- 2013-06-10 AU AU2013274619A patent/AU2013274619B2/en active Active
- 2013-06-10 CN CN201380030478.2A patent/CN104350048B/zh active Active
- 2013-06-10 TW TW102120593A patent/TWI571470B/zh active
- 2013-06-10 PE PE2014002405A patent/PE20150228A1/es active IP Right Grant
- 2013-06-10 PL PL13730444T patent/PL2858987T3/pl unknown
- 2013-06-10 ES ES13730444.0T patent/ES2675314T3/es active Active
- 2013-06-10 HU HUE13730444A patent/HUE039210T2/hu unknown
- 2013-06-10 HR HRP20180815TT patent/HRP20180815T8/hr unknown
- 2013-06-10 CA CA2876359A patent/CA2876359C/en active Active
- 2013-06-10 LT LTEP13730444.0T patent/LT2858987T/lt unknown
- 2013-06-10 SI SI201331033T patent/SI2858987T1/en unknown
- 2013-06-10 KR KR1020157000330A patent/KR102092984B1/ko active Active
- 2013-06-10 EP EP13730444.0A patent/EP2858987B1/en active Active
- 2013-06-10 DK DK13730444.0T patent/DK2858987T3/en active
- 2013-06-10 EA EA201492256A patent/EA024692B1/ru not_active IP Right Cessation
- 2013-06-10 MY MYPI2014703715A patent/MY169219A/en unknown
- 2013-06-10 WO PCT/US2013/044882 patent/WO2013188254A1/en not_active Ceased
- 2013-06-10 RS RS20180738A patent/RS57376B1/sr unknown
- 2013-06-10 MX MX2014014525A patent/MX356699B/es active IP Right Grant
- 2013-06-10 NZ NZ703632A patent/NZ703632A/en unknown
-
2014
- 2014-11-28 TN TN2014000499A patent/TN2014000499A1/fr unknown
- 2014-12-04 IL IL236074A patent/IL236074A/en active IP Right Grant
- 2014-12-09 PH PH12014502747A patent/PH12014502747B1/en unknown
- 2014-12-10 CL CL2014003361A patent/CL2014003361A1/es unknown
-
2015
- 2015-01-08 CO CO15003999A patent/CO7160032A2/es unknown
- 2015-01-09 ZA ZA2015/00161A patent/ZA201500161B/en unknown
-
2018
- 2018-07-13 CY CY20181100733T patent/CY1120432T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3124475B1 (en) | Quinazolines as potassium ion channel inhibitors | |
| US9242966B2 (en) | Phthalazines as potassium ion channel inhibitors | |
| EP2970295B1 (en) | Pyrrolopyridazines as potassium ion channel inhibitors | |
| DK2858987T3 (en) | PHOSPHORAMIC ACID PRODRUGS OF 5- [5-PHENYL-4- (PYRIDIN-2-YLMETHYLAMINO) QUINAZOLIN-2-YL] PYRIDIN-3-SULPHONAMIDE | |
| EP2970294B1 (en) | Pyrrolotriazines as potassium ion channel inhibitors | |
| HK1203928B (en) | Phosphoramidic acid prodrugs of 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide | |
| US20060128726A1 (en) | Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations | |
| CN101228151B (zh) | 4-甲基-n-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的盐 | |
| HK40018229A (en) | Quinazolines as potassium ion channel inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180220 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250430 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260722 |